World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).

ABSTRACT: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment. The availability of new disease-modifying therapies has made successful treatment a reality. Transthyretin amyloid cardiomyopathy can be either age-related (wild-type form) or caused by mutations in the TTR gene (genetic, hereditary forms). It is a systemic disease, and while the genetic forms may exhibit a variety of symptoms, a predominant cardiac phenotype is often present. This document aims to provide an overview of ATTR-CM amyloidosis focusing on cardiac involvement, which is the most critical factor for prognosis. It will discuss the available tools for early diagnosis and patient management, given that specific treatments are more ef

SUBMITTER: Brito D 

PROVIDER: S-EPMC10607607 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature